Table. Patient Demographic and Clinical Characteristics.
| Characteristic | Patients with confirmed hypercalcemiaa | ||
|---|---|---|---|
| With PTH level measured (n = 215)b | Without PTH level measured (n = 180) | P value | |
| Age, median (IQR), y | 72 (59-78) | 69 (58-77) | .09 |
| Body mass index, median (IQR)c | 26.4 (23.28-30.95) | 27.03 (23.68-31.28) | .49 |
| Sex | |||
| Female | 138 (64.2) | 123 (68) | .52 |
| Male | 74 (34.4) | 57 (32) | |
| Declined | 1 (0.5) | 0 | |
| Other | 2 (0.9) | 0 | |
| Raced | |||
| Alaska Native | 1 (0.5) | 1 (0.6) | .60 |
| Asian | 17 (7.9) | 11 (6) | |
| Black/African American | 36 (16.7) | 26 (14) | |
| White | 136 (63.3) | 114 (63) | |
| Declined | 10 (4.7) | 6 (3) | |
| Othere | 13 (6) | 21 (12) | |
| Unknown | 2 (0.9) | 1 (0.6) | |
| Ethnicityd | |||
| Hispanic or Latino | 14 (6.5) | 11 (6) | .47 |
| Non-Hispanic or non-Latino | 185 (86) | 161 (89) | |
| Declined | 14 (6.5) | 7 (4) | |
| Unknown | 2 (0.9) | 1 (0.6) | |
| Baseline laboratory values, median (IQR) | |||
| Total calcium level, mg/dL | 10.65 (10.55-10.8) | 10.65 (10.55-10.75) | .41 |
| eGFR level, mL/min/1.73 m2 | 69 (52-84) | 76 (61-90) | .004 |
| Vitamin D (25-hydroxyvitamin D) level, ng/mL | 35.5 (26.75-45.25) | 34 (24.75-45) | .49 |
| Baseline comorbidities | |||
| Osteoporosis or osteopenia | 60 (27.9) | 43 (24) | .42 |
| Nephrolithiasis | 16 (7.4) | 19 (11) | .29 |
| Any fracture | 33 (15.3) | 32 (18) | .59 |
| Male hypogonadism | 9 (4.2) | 4 (2) | .40 |
| Hyperthyroidism | 3 (1.4) | 4 (2) | .71 |
Abbreviations: eGFR, estimated glomerular filtration rate; PHPT, primary hyperparathyroidism; PTH, parathyroid hormone.
SI conversion factors: To convert PTH level to ng/L, multiply by 1; total calcium to mmol/L, multiply by 0.25; eGFR to mL/s/m2, multiply by 0.0167; and vitamin D (25-hydroxyvitamin D) to nmol/L, multiply by 2.496.
Data are presented as number (percentage) of patients unless otherwise indicated. Confirmed hypercalcemia was defined as 2 instances of an elevated serum total calcium concentration (>10.4 mg/dL, our institution’s upper limit of the 95% laboratory reference range) in a 6-month interval.
Of these patients, 213 were found to have PHPT, as evidenced by an elevated or inappropriately normal PTH level (>11 pg/mL).
Calculated as weight in kilograms divided by height in meters squared.
Race and ethnicity were self-reported and were provided for comprehensive demographic data to analyze whether certain races and ethnicities were evaluated differently for PHPT.
Other was not specified further in the electronic medical record database.